Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations.
Publication
, Journal Article
Peters, KB; Geurts, M
Published in: Neurooncol Pract
February 2025
Duke Scholars
Published In
Neurooncol Pract
DOI
ISSN
2054-2577
Publication Date
February 2025
Volume
12
Issue
Suppl 1
Start / End Page
i2 / i5
Location
England
Citation
APA
Chicago
ICMJE
MLA
NLM
Peters, K. B., & Geurts, M. (2025). Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations. Neurooncol Pract, 12(Suppl 1), i2–i5. https://doi.org/10.1093/nop/npae076
Peters, Katherine B., and Marjolein Geurts. “Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations.” Neurooncol Pract 12, no. Suppl 1 (February 2025): i2–5. https://doi.org/10.1093/nop/npae076.
Peters KB, Geurts M. Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations. Neurooncol Pract. 2025 Feb;12(Suppl 1):i2–5.
Peters, Katherine B., and Marjolein Geurts. “Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations.” Neurooncol Pract, vol. 12, no. Suppl 1, Feb. 2025, pp. i2–5. Pubmed, doi:10.1093/nop/npae076.
Peters KB, Geurts M. Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations. Neurooncol Pract. 2025 Feb;12(Suppl 1):i2–i5.
Published In
Neurooncol Pract
DOI
ISSN
2054-2577
Publication Date
February 2025
Volume
12
Issue
Suppl 1
Start / End Page
i2 / i5
Location
England